Medical Devices

Kodiak Sciences is raising crucial capital with a stock offering, diluting investors but fueling its late-stage retinal drugs. Is this a necessary lifeline or a red flag?

Tiziana's CEO doubles down with a major share purchase, signaling deep faith in a novel MS drug, even as market signals send mixed messages.

One firm is ditching market predictions for a new approach: debunking costly myths. Here’s why this matters for healthcare leaders and investors.

When a superstorm threatened a 10,000-person conference, one firm's crisis response offered a masterclass in resilience with lessons for the entire industry.

Anixa Biosciences now fully controls its breast cancer vaccine after promising Phase 1 data. What does this strategic move mean for investors and medicine?

A Minneapolis firm is testing a graft that helps the body rebuild its own arteries. This could end a painful, risky part of traditional heart bypass surgery.

An Indiana biotech prepares for biotech's biggest stage, showcasing a pipeline that offers new hope for chronic endocrine and metabolic disorders.

A new FDA clearance for its AI software enhances Hyperfine's portable MRI, positioning it to disrupt the lucrative stroke diagnostics market. Here's why.

How a strategic pharma pact between Duchesnay and Mochida to bring a vital pregnancy drug to Japan offers a blueprint for stable returns in complex markets.

A new drug for a leading cause of blindness missed its primary goal, yet its unique ability to improve vision offers new hope for millions of patients.

A pivotal trial success in lupus for BTK inhibitor orelabrutinib not only offers new hope for patients but also validates Zenas BioPharma's strategy.

Vanda Pharmaceuticals submits its novel GPP therapy, imsidolimab, for FDA review, offering new hope for patients and bolstering its rare disease portfolio.

Beyond software, a new accelerator offers hardware startups a rare advantage, bridging the gap from university labs to investor-ready prototypes.

Two Bay Area event firms gain a key certification, strategically positioning them to tap into the lucrative healthcare conference market via supplier diversity.

Amid a $2.37B buyout, Weiss Asset Management's increased stake in Avadel Pharma raises questions. Is it a vote of confidence or a strategic power play?

With FDA alignment for its pivotal Phase 3 trial, Oncolytics Biotech is poised to bring the first immunotherapy to the challenging pancreatic cancer landscape.

United Imaging Intelligence's new AI agents can reason, act, and report. But are hospitals ready for the business and ethical hurdles of this new era?

A positive EU opinion for Sobi's Aspaveli could bring the first-ever targeted treatment for two rare kidney diseases, shaking up a market desperate for innovation.

Acadia's new powder form of the only Rett syndrome drug offers families vital choice, easing daily care and showing the power of patient-led innovation.

Sectra posts record profits, but a costly cloud transition and security delays test its strategy. Is this the price of future leadership in AI healthcare?